SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ismaiel M)
 

Sökning: WFRF:(Ismaiel M) > Divergent effects o...

Divergent effects of metformin on an inflammatory model of Parkinson’s disease

Tayara, Khadija (författare)
University of Seville,University Hospital Virgen del Rocío
Espinosa-Oliva, Ana M. (författare)
University of Seville,University Hospital Virgen del Rocío
García-Domínguez, Irene (författare)
University Hospital Virgen del Rocío,University of Seville
visa fler...
Ismaiel, Afrah Abdul (författare)
University Hospital Virgen del Rocío,University of Seville
Boza-Serrano, Antonio (författare)
Lund University,Lunds universitet,Neuroinflammation,Forskargrupper vid Lunds universitet,Lund University Research Groups
Deierborg, Tomas (författare)
Lund University,Lunds universitet,Neuroinflammation,Forskargrupper vid Lunds universitet,Lund University Research Groups
Machado, Alberto (författare)
University of Seville,University Hospital Virgen del Rocío
Herrera, Antonio J. (författare)
University Hospital Virgen del Rocío,University of Seville
Venero, José L. (författare)
University Hospital Virgen del Rocío,University of Seville
de Pablos, Rocío M. (författare)
University of Seville,University Hospital Virgen del Rocío
visa färre...
 (creator_code:org_t)
2018-11-21
2018
Engelska.
Ingår i: Frontiers in Cellular Neuroscience. - : Frontiers Media SA. - 1662-5102. ; 12
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The oral antidiabetic drug metformin is known to exhibit anti-inflammatory properties through activation of AMP kinase, thus protecting various brain tissues as cortical neurons, for example. However, the effect of metformin on the substantia nigra (SN), the main structure affected in Parkinson’s disease (PD), has not yet been studied in depth. Inflammation is a key feature of PD and it may play a central role in the neurodegeneration that takes place in this disorder. The aim of this work was to determine the effect of metformin on the microglial activation of the SN of rats using the animal model of PD based on the injection of the pro-inflammogen lipopolysaccharide (LPS). In vivo and in vitro experiments were conducted to study the activation of microglia at both the cellular and molecular levels. Our results indicate that metformin overall inhibits microglia activation measured by OX-6 (MHCII marker), IKKβ (pro-inflammatory marker) and arginase (anti-inflammatory marker) immunoreactivity. In addition, qPCR experiments reveal that metformin treatment minimizes the expression levels of several pro- and anti-inflammatory cytokines. Mechanistically, the drug decreases the phosphorylated forms of mitogen-activated protein kinases (MAPKs) as well as ROS generation through the inhibition of the NADPH oxidase enzyme. However, metformin treatment fails to protect the dopaminergic neurons of SN in response to intranigral LPS. These findings suggest that metformin could have both beneficial and harmful pharmacological effects and raise the question about the potential use of metformin for the prevention and treatment of PD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

AMPK
Animal model
Metformin
Microglia activation
Neuroinflammation
Parkinson’s disease

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy